Found vs. Oak Longevity: prices, fine print, and the honest verdict

Tirzepatide pricing

Found: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front). Oak Longevity does not offer tirzepatide.

Semaglutide pricing

On semaglutide, Oak Longevity wins at $133 versus $289 all-in — $156/mo apart. Found: Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms). Oak Longevity: Semaglutide runs $133 a month all-in.

Transparency

Found: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. Oak Longevity: Source-verified (verified 2026-08-08); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Found: none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. Oak Longevity: none stated; no subscription.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: Found holds $289 on every rung (four-month titration: exactly $1,156). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

On semaglutide, Oak Longevity prices at $133 against $289 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Found's ranked figure is $289, with no membership to add; Oak Longevity publishes no figure to normalize. 2 · Maintenance basis. Found is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Found: standing $289, prepaid $169 effective (12-month plan paid up front) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Found: third-party-reported, read 2026-08-05; Oak Longevity: source-verified, read 2026-08-08. 5 · Pharmacy weighed. Found names no pharmacy; Oak Longevity names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Found: no membership — the medication figure is the billed figure; prepaid 12-month plan paid up front at $169/mo effective; membership recurs; prepaid terms are paid up front; commitment: none month-to-month; prepaid terms for lowest rate. Oak Longevity: no membership — the medication figure is the billed figure; no subscription; commitment: none stated. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Found carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Oak Longevity carries source-verified pricing (last read 2026-08-08); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from Found to Oak Longevity (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Found: shipping included; consultation included; async visit model. Oak Longevity: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Found if you want a price that survives titration; you'll prepay for the $169 effective rate; you want the insurance paperwork done for you. Pick Oak Longevity if the semaglutide line is cheaper here. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are ShedRx at $289 (dose-scaled, no membership); OrderlyMeds at $299 (flat, no membership); SkinnyRx at $299 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,920/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.